source
- Novartis investors grow wary as drug setbacks spark scrutiny of M&A strategyInvestors in Novartis are intensifying their examination of the company’s recent dealmaking after a series of setbacks involving drugs that were brought in through mergers and acquisitions. The hei…
- Karyopharm Secures One-Month Debt Extension While Awaiting Xpovio DecisionKaryopharm Therapeutics, facing cash constraints, has negotiated a temporary reprieve on a $15.8 million debt that was due. Under the agreement, lenders and noteholders will refrain from enforceme…